SGN-15

SGN-15

A formulation of a monoclonal antibody bound to a cytotoxic antibiotic (BR96-doxorubicin) which made it to Phase-II trials with “encouraging trends” reported for managing lung cancer. Its sponsorship ceased in 2005.
References in periodicals archive ?
"The number of clinical trials was expanded with the initiation of the SGN-15 study in lung cancer.
On August 14, 2001, the company announced a manufacturing agreement with ICOS Corporation for the monoclonal antibody component of its lead product candidate, SGN-15. Under the terms of the agreement, ICOS will perform process development, scale-up and GMP manufacturing.
On August 21, 2001, Seattle Genetics announced the initiation of a phase II clinical trial for patients with non-small cell lung cancer with its product candidate, SGN-15, a monoclonal-antibody drug conjugate.